This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.283

Afatinib in combination with pembrolizumab in patients with stage IIIB/IV squamous cell carcinoma of the lung

Jonathan W. Riess, Jaafar Bennouna, Luis Paz-Ares, Michael J. Chisamore, Charlotte Lybek Lind, Behbood Sadrolhefazi, Benjamin Levy

1200.283 TiP - WCLC 2017 Poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

New developments in the treatment of advanced squamous cell lung cancer: focus on Afatinib

Hirsh V. Onco Targets Ther. 2017 May 11;10:2513-2526

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Felip E, et al. Clinical Lung Cancer, In press

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, et al. Lancet Oncol 2015;16(8):897–907

ErbB family receptors and afatinib mechanism of action video

MOA  Video

2 min 40 secs
Rate this